Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and...
-
Upload
sterling-sailer -
Category
Documents
-
view
219 -
download
1
Transcript of Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and...
![Page 1: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/1.jpg)
Cholesterol: The Expanded Lipid
ProfileBen Brown MDDecember 19, 2011Thanks also to Wendy K and Fasih H
![Page 2: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/2.jpg)
Outline
What is the expanded lipid panel?
Why order it?
How to order it?
What to do with results?
Cases
Questions
![Page 3: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/3.jpg)
Cases1. 54 y/o woman with no risk factors and an
LDL of 189. She does not want meds.
2. 35 y/o Latino male with new onset DM and a “perfect” lipid panel.
3. 40 y/o male who comes in and tells you that his Dad and brother both had their first MI at 45y/o. His lipids look more or less normal.
4. Bonus Case from Wendy
5. A 72 y/o woman obese, HTN, IGT, depression. What is my risk of heart disease or stroke?
![Page 4: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/4.jpg)
Why bother with more?1. Not all lipids are the same risk:
impact of LDL size & number HDL subtypes
2. In selected patients: Other Risk Factors missed with typical lipid panel
Lp(a) hsCRP
FHx early CADz and close to normal lipids
Metabolic Syndrome and need more info to change
High Lipids and wants to avoid statins or difficulty tolerating
![Page 5: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/5.jpg)
Question?In addition to the standard lipid profile, What is
included in the expanded lipid panel?
A. LDL subtypes (apoB)
B. HDL subtypes (2 and 3)
C. LPa
D. hsCRP
E. Homocysteine
F. All of the above
G. It depends
![Page 6: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/6.jpg)
What is there and How to Order?
![Page 7: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/7.jpg)
Expanded Lipid Profiles
Quest: expanded lipid panel (or lipid- or homocyt- with homocysteine)
Lipoprotein Particle Analysis (LPP) Spectracell
Berkeley HeartLab (BHL)
NMR: Liposcience
VAP: Atherotec
Hunter: Cardiovascular Risk/Metabolic Syndrome
![Page 8: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/8.jpg)
LDL: particle size and numberBigger is Better
Small LDL is the bad guy why? it goes across the
endothelium more readily absorbed by
macrophages more readily = foam cells…bad
Less is more (better)
ApoB ( one per particle) scientifically accepted measurement for LDL particle number. Can be used to Monitor statin therapy.
![Page 9: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/9.jpg)
Apo B (LDL pattern)Nl <60
![Page 10: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/10.jpg)
Small LDL= pattern B
![Page 11: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/11.jpg)
Case 1
According to ATP 3 Guidelines what would you recommend for our 54 y/o woman with no risk factors and an LDL of 189?
A. Life style with a goal of LDL 160
B. Life style with a goal of LDL 130
C. Start a Statin
D. Start Bile Acid Binder or Niacin
![Page 12: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/12.jpg)
Case 1
According to ATP 3 Guidelines what would you recommend for our 54 y/o woman with no risk factors and an LDL of 189?
A. Life style with a goal of LDL 160
B. Life style with a goal of LDL 130
C. Start a Statin
D. Start Bile Acid Binder or Niacin
![Page 13: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/13.jpg)
ATP 3 Guidelines-surprisingly generous
Google: ATP 3 Guidelines at a glance
![Page 14: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/14.jpg)
ATP3 Guidelines Step 3:risk factors
![Page 15: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/15.jpg)
Her expanded panel results
LDL=189, TG=102, HDL =63
apoB 20 (low)
hsCRP 0.5 (normal)
HDL2 (normal)
HDL3 (normal)
Lp(a) low
Later an AIC was 5.0
What if her Apo B or hsCRP or AIC was high?
![Page 16: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/16.jpg)
Treatment of small dense LDL Treat LDL cholesterol and think
Metabolic or Inflammation
Insulin Resistance (glycocylation) Check AIC and treat accordingly Note: I start metformin early in someone who does not make LS
changes easily (provider choice).
Inflammation (oxidation) Check hsCRP Think of antioxidants Will cover with hsCRP
![Page 17: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/17.jpg)
HDLHDL 2 (a and b)
Again bigger is better
Reverse cholesterol transport
Antioxidant effect
Increases with exercise, fish oil, niacin, fibric acid, statin and niacin combo’s, moderate alcohol consumption.
HDL 3
Smaller less protective
(signal of inefficient transport)
![Page 18: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/18.jpg)
Case 2
35 y/o Latino male with new onset DM and a “perfect” lipid panel.
TC 168
HDL 41
TG 115
LDL 104
Expanded Panel
Apo B high
HDL 2 low/3 normal
Hs CRP 1.7
Lp(a) normal
What would you do?
![Page 19: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/19.jpg)
Treatment of Low HDL 2 Exercise
Niacin
Moderate alcohol consumption (both 2 and 3)
Stop smoking
?Fish oil
?statin, Fibric Acids, Bile acid binder might start for high apoB
Mediterranean Diet, fish oils, consider probiotic for his high CRP
![Page 20: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/20.jpg)
LipoProtein (a)Treatment options:• Lp(a) is an
inherited abnormal protein attached to LDL.
• Normal level < 30 mg/dL
• Lp(a) increases coagulation and triples CVD risk.
Niacin
NAC 600 mg twice daily
![Page 21: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/21.jpg)
Case 3
40 y/o male who comes in and tells you that his Dad and brother both had their first MI at 45y/o. His lipids look more or less normal.
Expanded panel results
Lp(a) high (104)
Others normal
What would you do?
![Page 22: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/22.jpg)
Lp(a)
![Page 23: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/23.jpg)
Bonus case: Wendy’s patient 58 yo woman, slender, healthy eater with h/o ischemic
stroke age 58. Year later, ischemic bowel.
![Page 24: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/24.jpg)
InflammationHs-CRP
Inflammatory marker
Better then ESR and leucocytes for predicting vascular events
Low Risk level < 1.0 mg/L
Lp-PLA2
Slightly more specific for vascular inflammation
Low risk <200 mg/ml
![Page 25: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/25.jpg)
hsCRP
![Page 26: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/26.jpg)
![Page 27: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/27.jpg)
Treatment of increased hsCRP Look for cause: inflammation, infection,
trauma.
Consider checking Lp-PLA2 (endothelial inflammation)
Anti-inflammatory regimen Diet (Mediterranean anti-inflammatory or mod
elim) Exercise (any is better) Fish oils (dose by EPA/DHA 2-6g a day) Probiotics (10 billion org a day) Vit D (check level and treat to 50) Decrease Stress and support good sleep
(cortisol)
![Page 28: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/28.jpg)
4th Patient
• 72 y/o woman obese, HTN, IGT, depression.
• “What is my risk of heart disease or stroke?”
• How do you answer this question?
• Very Concrete thinker
• Can you do it in a way that furthers the patients motivation to change and is affordable?
![Page 29: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/29.jpg)
Thoughts after test
Routine lipid panel
• At Goal– HDL = 65– VLDL = 18– Chol/HDL ratio =3.2– TG’s = 90
• moderate risk– TC = 211– LDL = 128– Non-HDL chol = 146
Advanced Risk Markers
• High Risk– hsCRP = 4.88 [<1] – sd-LDL = 36.2 [20]
• Moderate Risk– Apo B 113 [<60]– Homocysteine 11.2 (<10)
At Goal– Lp-PLA2 185.4 (<200)
![Page 30: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/30.jpg)
How to treat• NCEP –ATC diet with goal
of dropping 5-10% weight
• Lower carbohydrate, higher fiber diet
• Omega 3 fats; substitute olive oil
• Screen for DM, hypothyroidism
• Lower LDL*
![Page 31: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/31.jpg)
ECW tricks: 3 other tests you may want…
![Page 32: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/32.jpg)
Summary High apoB = Small dense LDL ~ metabolic syndrome
check AIC, treat LDL earlier, LS changes, consider earlier metformin, check hsCRP
Low HDL (especially low High HDL 2) Exercise, Niacin, moderate ETOH
High Lp(a) bad Niacin, NAC
High hsCRP (cardio CRP) > 1.0 r/o infection, inflammation, trauma. Repeat test/ck lp-PLA2 Anti-inflam regimen (diet, ex, stress, fish oil, probiotic,
antioxidants)
Homocysteine: a definite risk factor, interventions lower it, ?if that makes a difference unless they have the condition hyperhomocysteinuria (rare).
![Page 33: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/33.jpg)
Homocysteine
Methylation (if high also check B12/folate/methylmalonic acid) Functions primarily to protect DNA
How to help For most Mediterranean Diet adequate, if still a
problem may need supplementation B6 25 micrograms/d B12 1000micrograms/d Folate 800micrograms/d (may need as methyl THF)
![Page 34: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/34.jpg)
Progression of Drug Therapy in Primary Prevention
If LDL goal not achieved, intensifyLDL-lowering therapy
If LDL goal not achieved, intensify drug therapy or refer to a lipid specialist
Monitor response and adherence to therapy
• Start statin or bile acid sequestrant or nicotinic acid
• Consider higher dose of statin or add a bile acid sequestrant or nicotinic acid
6 wks
6 wks
Q 4-6 mo
• If LDL goal achieved, treat other lipid risk factors
Initiate LDL-lowering drug therapy
![Page 35: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/35.jpg)
Lipids Background
Cholesterol Functions
1. Plasma Membranes
2. Myelinated structures in the CNS
3. Inner Mitochondrial Membranes
4. Bile Acids
5. Steroid Hormones and Sex Hormones
6. Ergosterol (UV skin) Vit D3
![Page 36: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/36.jpg)
Lipids Background
Lipids in Atherosclerosis Dys-Function
1. Endothelium and damage
2. LDL and Macrophages
3. Oxidized LDL and Foam Cells Also glycosylated and acetylated LDL
4. Plaque and rupture
5. HDL as scavenger
![Page 37: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/37.jpg)
Cholesterol General
Total Cholesterol/HDL ratio (TC/HDL)
Best Lipid predictor of CHD in Framingham Study
TC/HDL ratio 1 unit = CHD risk by 60%
Eg TC/HDL ratio of <4 is normal
6 = 120% increased risk
3 = 60% decreased risk
![Page 38: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/38.jpg)
JAMA: 200968 Studies: 300,000 patients
Mean fu 6 years
Risk for coronary disease was associated with
higher values of •non–HDL-C and LDL-C,
•higher ratios of non–HDL-C/HDL-C
•apo B/A1•lower values of HDL-C. •not associated with triglyceride levels
•No difference in risk prediction was observed
between fasting and nonfasting measurements.
Di Angelantonio E et al. for the Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009 Nov 11; 302:1993.
Risk for coronary disease was associated with higher values of •non–HDL-C and LDL-C,•higher ratios of non–HDL-C/HDL-C•apo B/A1 (LDL/HDL)•lower values of HDL-C. •not associated with triglyceride levels•No difference in risk prediction was observed between fasting and non-fasting measurements.
![Page 39: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/39.jpg)
IM4U Treatment Pyramid
Environment ResourcesRelationships
![Page 40: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/40.jpg)
IM4U Treatment Pyramid (expanded)
Environment ResourcesRelationships
![Page 41: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/41.jpg)
Drug Therapy
1) HMG CoA Reductase Inhibitors (Statins)
Reduce LDL-C 18–55% & TG 7–30%
Raise HDL-C 5–15%
Major side effects Myopathy Increased liver enzymes
Contraindications Absolute: liver disease Relative: use with certain drugs
![Page 42: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/42.jpg)
HMG CoA Reductase Inhibitors (Statins) (continued)
Demonstrated Therapeutic Benefits
Reduce major coronary events
Reduce CHD mortality
Reduce coronary procedures (PTCA/CABG)
Reduce stroke
Reduce total mortality
![Page 43: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/43.jpg)
Statins: Drug-Nutrient Side Effects
Nutrients Depleted
Coenzyme Q10: Statins inhibit the enzyme HMG CoA reductase that is required to make cholesterol and Coenzyme Q10.
Could explain myalgia, exercise intolerance, myoglobuinuria
Also, Selenium, Zinc, Copper
Lower serum PUFA’s and alter the relative % of omega 6:3 fats
Arch Neurol 2004;61(6):889Nutr Metab Cardiovasc Dis 2005; 15(1): 36
![Page 44: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/44.jpg)
Drug Therapy
2) Bile Acid Sequestrants
Ex: cholestyramine, colestipol, colesevelam
Major actions
Reduce LDL-C 15–30%
Raise HDL-C 3–5% May increase TG
Contraindications Dysbetalipoproteinemia Raised TG (especially >400 mg/dL)
![Page 45: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/45.jpg)
Bile Acid Sequestrants (continued)
Demonstrated Therapeutic Benefits
Reduce major coronary events Reduce CHD mortality
Side effects GI distress/constipation Decreased absorption of other drugs Decreases beta-carotene, calcium, folate, Fe,
Mg, Vit B12, D, E, K & zinc (cholestyramine)
![Page 46: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/46.jpg)
Drug Therapy
3) Nicotinic Acid
Major actions Lowers LDL-C 5–25% Lowers TG 20–50% Raises HDL-C 15–35%
Side effects: flushing, hyperglycemia, hyperuricemia, upper GI distress, hepatotoxicity
Contraindications: liver disease, severe gout, peptic ulcer
![Page 47: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/47.jpg)
Nicotinic Acid
Drug Form Dose Range
Immediate release 1.5–3 g(crystalline)
Extended release 1–2 g
Sustained release 1–2 g
![Page 48: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/48.jpg)
Nicotinic Acid (continued)
Demonstrated Therapeutic Benefits
Reduces major coronary events
Possible reduction in total mortality
![Page 49: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/49.jpg)
Drug Therapy
4) Fibric Acids
Example: gemfibrozil, fenofibrate, clofibrate
Major actions Lower LDL-C 5–20% (with normal TG) May raise LDL-C (with high TG) Lower TG 20–50% Raise HDL-C 10–20%
Contraindications: Severe renal or hepatic disease
![Page 50: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/50.jpg)
Fibric Acids (continued)
Demonstrated Therapeutic Benefits
Reduce progression of coronary lesions
Reduce major coronary events
Side effects: dyspepsia, gallstones, myopathy
Drug-nutrient interactions: Decrease CoQ10 also, Vitamin E, (fenofibrate incr’s homocysteine)
![Page 51: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/51.jpg)
![Page 52: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/52.jpg)
![Page 53: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/53.jpg)
![Page 54: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/54.jpg)
![Page 55: Cholesterol: The Expanded Lipid Profile Ben Brown MD December 19, 2011 Thanks also to Wendy K and Fasih H.](https://reader035.fdocuments.net/reader035/viewer/2022062515/56649c985503460f94953fe8/html5/thumbnails/55.jpg)